The ALT-defined phenotype of metabolic dysfunction-related liver disease has been used by researchers to establish a link between NAFLD (MDLD) and an elevated risk of malignancies other than the liver, such as breast, colon, liver, lung, and prostate (MDLD) (8). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.